Phase I/II trial for advanced Gastric or Gastroesophageal junction cancer (Combination therapy) in South Korea
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2018
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- 10 Oct 2018 New trial record
- 01 Oct 2018 According to LSK Biopharma media release, that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a Phase I/IIa study protocol to investigate the combination of rivoceranib and paclitaxel.
- 01 Oct 2018 According to LSK Biopharma media release, patient enrollment start in in October 2018.